DEFA14A: ISS Backs Neuphoria Board in Proxy Contest

Leading proxy advisory firm ISS recommends Neuphoria shareholders vote for the company's director nominees, supporting the board's strategic review amidst a proxy contest.

Summary

• Institutional Shareholders Services (ISS) has recommended that Neuphoria shareholders vote FOR BOTH of the Company's director nominees, Peter Miles Davies and David Wilson, on the WHITE proxy card.
• ISS recommends WITHHOLD votes for the dissident nominees, Doberstein and Smith, put forth by Lynx1 Capital Management.
• The ISS report recognized that Neuphoria's Board acted appropriately and proactively in response to the BNC210 Phase 3 clinical trial data readout and an ongoing capital raise.
• Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for neuropsychiatric disorders.
• The lead drug candidate, BNC210, an oral therapy for post-traumatic stress disorder (PTSD), missed its primary and secondary endpoints in the AFFIRM-1 Phase 3 clinical trial on October 20, 2025.
• Following the trial failure, Neuphoria halted development of BNC210 in social anxiety disorder and initiated a strategic review.
• The company also has a strategic partnership with two drugs in early-stage clinical trials for Alzheimer's disease and other central nervous system conditions, along with preclinical programs (7 nicotinic acetylcholine receptor next generation and Kv3.1/3.2) in lead optimization.

Sentiment

Score: 6

Explanation: The filing reports a positive outcome for Neuphoria's current management in a proxy contest, with ISS recommending shareholders vote for the company's nominees. This provides a degree of stability and validation for the board's strategic review process, despite the prior negative news of a failed Phase 3 clinical trial.

Positives

• ISS, a leading independent proxy advisory firm, recommended shareholders vote FOR Neuphoria's director nominees, supporting the current Board.
• ISS recognized the Board's appropriate and proactive actions regarding the BNC210 Phase 3 data readout and ongoing capital raise.
• The Board proactively raised capital, strengthening the company's balance sheet for the strategic review.
• ISS concluded that Lynx1 Capital Management, the dissident, has not presented a compelling case for change.
• The Board has committed to transparency in its strategic alternatives process and has provided recent updates to shareholders.
• The Board's rejection of the dissident's offer was deemed defensible, and the dissident was invited to participate in the strategic review on similar terms to other parties.

Negatives

• The BNC210 Phase 3 clinical trial (AFFIRM-1) for PTSD missed its primary and secondary endpoints.
• Development of BNC210 in social anxiety disorder has been halted.
• Neuphoria is currently engaged in a proxy contest with Lynx1 Capital Management, which is seeking to elect two director candidates in opposition to the Board's nominees.

Risks

• Neuphoria's ability to develop and expand its business and successfully complete development of its current product candidates is uncertain.
• The timing of commencement and/or completion, as well as any successful or other outcome of various clinical trials, is subject to significant uncertainty.
• Receipt of data and current and future collaborations for the development and commercialization of product candidates may not materialize as expected.
• The market for drugs to treat central nervous system diseases and pain conditions is competitive and uncertain, impacting the company's ability to realize commercial potential.
• The company's regulatory strategy related to its clinical trials and the regulatory pathway to any next stage in development or commercialization may face challenges.
• Neuphoria's financial resources, capital allocation, and corporate development strategy are subject to risks.
• The Board's review of strategic alternatives and evaluation of offers from third parties may not result in the desired outcome or maximum shareholder value.
• Certain forward-looking statements involve contracts, licenses, and arrangements with third parties whose clinical trial and research and development projects are out of Neuphoria's control, potentially leading to termination or delays and impacting milestone payments or product progress.
• Future events and actual results could differ materially from forward-looking statements due to a number of important factors.

Future Outlook

Neuphoria is proceeding with a strategic review process, which the Board believes has the best opportunity to provide shareholders with maximum value. The company continues to advance its strategic partnerships with two drugs in early-stage clinical trials for Alzheimer's disease and other CNS conditions, as well as its 7 nicotinic acetylcholine receptor next generation and Kv3.1/3.2 preclinical programs.

Management Comments

• "We are very pleased that ISS has carefully reviewed the voting alternatives and has recommended that shareholders vote FOR BOTH of Neuphoria’s highly-qualified director nominees on the WHITE proxy card."
• "We are also pleased that in making its recommendation, ISS recognized that the Board has acted appropriately and proactively in connection with the data readout from the Phase 3 clinical trial of BNC210 and ongoing capital raise."
• "We believe that the strategic alternatives process that the Board is running needs to be seen to fruition and has the best opportunity to provide shareholders with maximum value."
• "We strongly urge all shareholders to follow the recommendation of ISS and vote TODAY on the WHITE proxy card FOR BOTH of Neuphoria’s director nominees to ensure that Neuphoria is best positioned to execute on its strategic alternatives process in order to provide shareholders with maximum value."

Industry Context

The biotechnology sector, particularly clinical-stage companies, is characterized by high-risk, high-reward drug development. A Phase 3 clinical trial failure, as experienced by Neuphoria with BNC210, is a significant setback that often triggers strategic re-evaluations and can lead to corporate governance challenges like proxy contests. The involvement of a leading proxy advisory firm like ISS is crucial in such disputes, as their recommendations heavily influence institutional investors' voting decisions, providing a benchmark for corporate governance practices within the industry.

Corporate Governance

Stakeholder Impact

• **Shareholders**: The ISS recommendation supports the current Board's nominees, influencing voting decisions and potentially impacting the company's strategic direction and future value realization. The strategic review aims to maximize shareholder value.
• **Employees**: The ongoing strategic review and adjustments to the pipeline, including halting BNC210 development for social anxiety disorder, could impact future projects and roles.
• **Patients/Customers**: The cessation of BNC210 development for social anxiety disorder means this potential therapy will not be available. Future therapeutic options depend on the success of other pipeline candidates and strategic partnerships.
• **Creditors**: The proactive capital raise and resulting stronger balance sheet could be viewed positively by creditors, indicating improved financial stability during a period of strategic re-evaluation.

Next Steps

• Shareholders are strongly urged to vote TODAY on the WHITE proxy card FOR BOTH of Neuphoria's director nominees.
• The Board will continue to execute on its strategic alternatives process to provide shareholders with maximum value.
• Neuphoria will continue advancing its strategic partnerships with two drugs in early-stage clinical trials for Alzheimer's disease and other CNS conditions.
• The company will also continue developing its 7 nicotinic acetylcholine receptor next generation and Kv3.1/3.2 preclinical programs.

Key Dates

Recommendation

While the ISS recommendation provides a degree of governance stability and supports the current management's strategic review, the underlying failure of the BNC210 Phase 3 clinical trial remains a significant negative. The company is in a critical phase of strategic re-evaluation, and the outcome of this review, along with the progress of its early-stage pipeline, will be key determinants of future value. Given these mixed signals and ongoing uncertainties, a 'hold' recommendation is appropriate until more definitive strategic plans or clinical data emerge.

Keywords

Biotechnology, Neuropsychiatric Disorders, Clinical-stage, Proxy Contest, ISS Recommendation, SEC Filing, Corporate Governance, BNC210, Phase 3 Trial, PTSD, Strategic Review, Capital Raise, NASDAQ: NEUP, Alzheimer's Disease, CNS